Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Gontero
Paolo
P
Clinica Urologica, University of Piemonte Orientale, Novara, Italy. gontero@med.unipmn.it
Marini
Luca
L
Frea
Bruno
B
D000283:Administration, Intravesical; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D018579:Patient Selection; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine